Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors | Zendy

Shinsuke Uchikawa | Zendy; Tomokazu Kawaoka | Zendy; Yuwa Ando | Zendy; Kenji Yamaoka | Zendy; Yumi Kosaka | Zendy; Yosuke Suehiro | Zendy; Yasutoshi Fujii | Zendy; Kei Morio | Zendy; Takashi Nakahara | Zendy; Eisuke Murakami | Zendy; Masataka Tsuge | Zendy; Akira Hiramatsu | Zendy; Michio Imamura | Zendy; Shoichi Takahashi | Zendy; Kazuaki Chayama | Zendy; Hiroshi Aikata | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors

Author(s) -

Shinsuke Uchikawa,

Tomokazu Kawaoka,

Yuwa Ando,

Kenji Yamaoka,

Yumi Kosaka,

Yosuke Suehiro,

Yasutoshi Fujii,

Kei Morio,

Takashi Nakahara,

Eisuke Murakami,

Masataka Tsuge,

Akira Hiramatsu,

Michio Imamura,

Shoichi Takahashi,

Kazuaki Chayama,

Hiroshi Aikata

Publication year - 2020

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000507815

Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , sorafenib , liver function , lenvatinib

Functional hepatic reserve is important when considering sequential tyrosine kinase inhibitor (TKI) therapy for patients with advanced hepatocellular carcinoma (HCC). We assessed albumin-bilirubin (ALBI) score and Child-Pugh class as indices of liver function during sorafenib and lenvatinib treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research